Sarah Gheuens - 10 Feb 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Medical Officer
Signature: /s/ William Cook, as attorney-in-fact for Sarah Gheuens
Issuer symbol: AGIO
Transactions as of: 10 Feb 2023
Net transactions value: -$21,558
Form type: 4
Filing time: 14 Feb 2023, 15:07:23 UTC
Previous filing: 28 Dec 2022
Next filing: 03 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+2,162	+14%	$0.000000	17,767	10 Feb 2023	Direct
transaction	AGIO	Common stock	Tax liability	$21,558	-758	-4.3%	$28.44	17,009	14 Feb 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Restricted stock units	Options Exercise	$0	-2,162	-50%	$0.000000	2,162	10 Feb 2023	Common stock	2,162		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2	The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.